Get the Stockscreener App
5.08
2.63%
0.13
After Hours:
4.98
-0.10
-1.97%
Champions Oncology Inc stock is traded at $5.08, with a volume of 14,220.
It is up +2.63% in the last 24 hours and down -12.56% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$4.95
Open:
$4.88
24h Volume:
14,220
Relative Volume:
1.53
Market Cap:
$70.58M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-30.49
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
-2.12%
1M Performance:
-12.56%
6M Performance:
-16.45%
1Y Performance:
-25.73%
1-Day Range:
$4.88
$5.13
1-Week Range:
$4.88
$5.3892
52-Week Range:
$4.88
$8.74
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.08 | 68.77M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - The Globe and Mail
Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth? - Sahm
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
Champions Oncology Inc. (CSBR) Slides 8.75% as Selling Pressure IntensifiesVolume Spike Alerts - dars.gov.et
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Rising costs push Champions Oncology (NASDAQ: CSBR) into 2026 loss - Stock Titan
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026 - TradingView
CSBR: Record revenue and positive adjusted EBITDA achieved, driven by core research services growth - TradingView
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline - TradingView
Champions Oncology Reports Record Annual Revenue of $59 Million - Eagle-Tribune
BRIEF-Champions Oncology Q4 Adjusted EPS USD 0.01 - TradingView
At fiscal year-end, Champions Oncology had $4.9M cash, no debt - Stock Titan
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CSBR|Champions Oncology Inc|Price:6.160|Chg%:+0.030 - TradingKey
Champions Oncology, Inc. Revenue Breakdown – MUN:2I3 - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3 - TradingView
Champions Oncology, Inc. Revenue Breakdown – FWB:2I3 - TradingView
CSBR Q4'25 Earnings: EPS estimate is (0.05) USD - TradingView
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
2 Microcaps With Gross Margin Catalysts - Yahoo Finance
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation - Yahoo! Finance Canada
Champions Oncology (CSBR.US) will release its earnings report after market close on July 27. - Moomoo
Champions Oncology to announce Q4 and FY26 results on July 27 - scanx.trade
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026 - ACCESS Newswire
Champions Oncology Schedules Year-End Results Call for 4:30 p.m. - Stock Titan
Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3 - TradingView
Brain Tumor Treatment Market Size To Exceed $7.17 Billion By 2035 - SNS Insider
RadioMedix Appoints Brian A. Markison to Board of Directors - Yahoo Finance UK
Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38Volatility Stop - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Enterprise value to EBIT forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Trading the Move, Not the Narrative: (CSBR) Edition - Stock Traders Daily
RXT Q1 2026 Earnings: EPS Misses Consensus by 69.49%, Shares SurgeProfit Recovery Report - dars.gov.et
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):